<DOC>
	<DOCNO>NCT02034006</DOCNO>
	<brief_summary>The primary objective study investigate current criterion drive re-treatment patient affect CNV secondary PM experience relapse disease first administration ranibizumab .</brief_summary>
	<brief_title>A Study Criteria Establishing Need Re-treatment With Ranibizumab Upon Relapse Patients With Visual Impairment Due Choroidal Neovascularization Secondary Pathologic Myopia .</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Myopia</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Vision Disorders</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<mesh_term>Angiogenesis Modulating Agents</mesh_term>
	<criteria>INCLUSION CRITERIA : Written inform consent give study related procedure perform Diagnosis active CNV secondary PM confirm complete ocular examination affect eye ( ) use follow criterion : Presence high myopia great 6D spherical equivalence Presence posterior change compatible pathologic myopia ( sign attenuation retinal pigment epithelium ( RPE ) choroid , mottle RPE , tilt disc , geographic atrophy RPE , Fuchs spot , posterior staphyloma , submacular hemorrhage , lacquer crack ) detect fundus ophthalmoscopy fundus photography Presence active leakage CNV observe fluorescein angiography ( FAG ) Presence intra subretinal fluid demonstrate Optical Coherence Tomography ( OCT ) BCVA &gt; 24 letter &lt; 78 letter test 4 meter star distance use ETDRSlike visual acuity chart Visual loss must due presence eligible type CNV relate PM base clinical ocular finding , FAG OCT. ( Also patient example 20/60 best visual acuity due PM history additional vision loss due CNV lesion include ) EXCLUSION CRITERIA : Patients inability comply study related procedure Pregnant nursing ( lactate ) woman woman childbearing potential UNLESS use effective contraception treatment Presence confirm systolic blood pressure &gt; 150 mmHg diastolic &gt; 90 mmHg time enrollment History stroke Any type advance , severe unstable medical condition treatment could significantly bias assessment clinical status interfere primary and/or secondary outcome evaluation put patient risk Presence active infectious disease intraocular inflammation either eye time enrollment Ocular disorder study eye may confound interpretation study result , compromise visual acuity require medical surgical intervention 12month study period ( include retinal detachment , cataract preretinal membrane macula ) History panretinal focal/grid laser photocoagulation involvement macular area study eye time History intraocular treatment antivascular endothelial growth factor ( VEGF ) , verteporfin photodynamic therapy ( vPDT ) intraocular surgery corticosteroid administration within one month study entrance Known hypersensitivity ranibizumab component ranibizumab formulation Simultaneous participation study include administration investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>pathological myopia</keyword>
	<keyword>choroidal neovascularization</keyword>
	<keyword>ranibizumab</keyword>
	<keyword>mono-bilateral</keyword>
	<keyword>poor visual acuity</keyword>
	<keyword>retinal disease</keyword>
	<keyword>eye disease</keyword>
	<keyword>Angiogenesis Inhibitors</keyword>
	<keyword>Angiogenesis Modulating Agents</keyword>
</DOC>